Tazobactam
Appearance
![]() | |
![]() | |
Clinical data | |
---|---|
AHFS/Drugs | International Drug Names |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChemCID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.108.321 |
Chemical and physical data | |
Formula | C10H12N4O5S |
Molar mass | 300.29g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Tazobactamis apharmaceutical drugthatinhibitsthe action of bacterialβ-lactamases,especially those belonging to theSHV-1andTEMgroups. It is commonly used as its sodiumsalt,tazobactam sodium.
Tazobactam is combined with theextended spectrum β-lactamantibioticpiperacillinin the drugpiperacillin/tazobactam,used in infections due toPseudomonas aeruginosa.Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that expressβ-lactamaseand would normally degrade piperacillin.[1]
Tazobactam was patented in 1982 and came into medical use in 1992.[2]
See also[edit]
References[edit]
- ^Yang Y, Rasmussen BA, Shlaes DM (August 1999). "Class A beta-lactamases--enzyme-inhibitor interactions and resistance".Pharmacology & Therapeutics.83(2): 141–151.doi:10.1016/S0163-7258(99)00027-3.PMID10511459.
- ^Fischer J, Ganellin CR (2006).Analogue-based Drug Discovery.John Wiley & Sons. p. 490.ISBN9783527607495.